Seroprevalence of SARS-CoV-2 Assessed by Four Chemiluminescence Immunoassays and One Immunocromatography Test for SARS-Cov-2

Frontiers in Public Health

Veronica Ferrucci¹  Antonio Pizzolante²  Denise Di Concilio²  Pellegrino Cerino²  Alfonso Gallo²  Maria Concetta Cuomo²  Gabriella Lo Conte²  Lucia Vassallo²  Annachiara Coppola²  Biancamaria Pierri³  Carlo Buonerba⁴  Luigi Atripaldi⁵  Giovanni Boccia⁶  Maria Triassi⁷  Daniela Pacella⁷  Alessandro Furno⁸  Michele Cennamo⁸  Paolo Romano⁸  Giuseppe Portella⁸  Daniela Terracciano⁸  Teresa Maria Sorbo⁸  Oriana Catapano⁹  Maurizio D'Amora⁹  Aldo Contina⁹  Giuseppe Perruolo⁹ 

[1] CEINGE Biotecnologie Avanzate, Naples, Italy;Centro di Referenza Nazionale per l'Analisi e Studio di Correlazione tra Ambiente, Animale e Uomo, Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici, Italy;Centro di Referenza Nazionale per l'Analisi e Studio di Correlazione tra Ambiente, Animale e Uomo, Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici, Italy;Department of Medicine, Surgery, and Dentistry ‘Scuola Medica Salernitana’, University of Salerno, Baronissi, Italy;Centro di Referenza Nazionale per l'Analisi e Studio di Correlazione tra Ambiente, Animale e Uomo, Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici, Italy;Regional Reference Center for Rare Tumors, Department of Oncology and Hematology, Azienda Ospedaliera Universitaria Federico II of Naples, Naples, Italy;Cotugno Hospital, Azienda Ospedaliera di Rilievo Nazionale Ospedali dei Colli, Naples, Italy;Department of Medicine, Surgery, and Dentistry ‘Scuola Medica Salernitana’, University of Salerno, Baronissi, Italy;Department of Public Health, Section of Hygiene, University of Naples Federico II, Naples, Italy;Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy;Unità Operativa Complessa Medicina di laboratorio P. O. San Paolo, Azienda Sanitaria Locale Naples 1 Centro, Naples, Italy;

关键词: SARS-CoV-2;    serological test;    seroprevalence;    immunoassays;    rapid tests;   

DOI  :  10.3389/fpubh.2021.649781

来源: Frontiers

【 摘 要 】

The onset of the new SARS-CoV-2 coronavirus encouraged the development of new serologic tests that could be additional and complementary to real-time RT-PCR-based assays. In such a context, the study of performances of available tests is urgently needed, as their use has just been initiated for seroprevalence assessment. The aim of this study was to compare four chemiluminescence immunoassays and one immunochromatography test for SARS-Cov-2 antibodies for the evaluation of the degree of diffusion of SARS-CoV-2 infection in Salerno Province (Campania Region, Italy). A total of 3,185 specimens from citizens were tested for anti-SARS-CoV-2 antibodies as part of a screening program. Four automated immunoassays (Abbott and Liaison SARS-CoV-2 CLIA IgG and Roche and Siemens SARS-CoV-2 CLIA IgM/IgG/IgA assays) and one lateral flow immunoassay (LFIA Technogenetics IgG–IgM COVID-19) were used. Seroprevalence in the entire cohort was 2.41, 2.10, 1.82, and 1.85% according to the Liaison IgG, Abbott IgG, Siemens, and Roche total Ig tests, respectively. When we explored the agreement among the rapid tests and the serologic assays, we reported good agreement for Abbott, Siemens, and Roche (Cohen's Kappa coefficient 0.69, 0.67, and 0.67, respectively), whereas we found moderate agreement for Liaison (Cohen's kappa coefficient 0.58). Our study showed that Abbott and Liaison SARS-CoV-2 CLIA IgG, Roche and Siemens SARS-CoV-2 CLIA IgM/IgG/IgA assays, and LFIA Technogenetics IgG-IgM COVID-19 have good agreement in seroprevalence assessment. In addition, our findings indicate that the prevalence of IgG and total Ig antibodies against SARS-CoV-2 at the time of the study was as low as around 3%, likely explaining the amplitude of the current second wave.

【 授权许可】

CC BY